康莱特注射液致脂肪超载综合征1例

Fat overload syndrome caused by Kanglaite injection:one case report

关键词:  康莱特  脂肪超载综合征  药物不良反应

Key words:  kanglaite  fat overload syndrome  adverse drug reactions

摘要:

目的：探讨康莱特注射液在临床上引起罕见的不良反应—脂肪超载综合征，提高临床医师对康莱特注射液相关不良反应的认识。 方法：报道1例住院患者使用康莱特注射液后发生脂肪超载综合征，根据诺氏药物不良反应评估量表并结合相关文献，评估该不良反应与康莱特注射液的关系和可能发生机制。 结果与结论：该患者发生的脂肪超载综合征与康莱特注射液的关联性为“很可能”。康莱特注射液是一种富含甘油三酯的脂肪乳剂，在排除输注不合理（快速或大剂量）情况下，终末期肿瘤导致甘油三脂廓清能力下降可能是该患者发生脂肪超载综合征的主要原因。因此临床上使用康莱特注射液需严格输注速度和总量，密切监测血脂、血常规、凝血及肝肾功能等指标，早期发现，及时治疗，可逆转患者病情，总体预后良好。

Abstract:

OBJECTIVE To recognize the rare adverse drug reaction (ADR) of Kanglaite injection —fat overload syndrome in order to improve its safe use by clinicians. METHODS This paper reported a case of fat overload syndrome after using Kanglaite injection. The Naranjo’s ADR evaluation Scale and related literature were used to summarize the association between the ADR and Kanglaite injection and its possible mechanism.RESULTS & CONCLUSIONS The association between fat overload syndrome and Kanglaite injection in this patient is considered “probable”. Kanglaite injection is a lipid emulsion rich in triglyceride. After excluding unreasonable infusion (rapid or high-dose), the decrease in triglyceride clearance ability caused by end-stage tumor may be the main cause of fat overload syndrome in the patient. Therefore, the clinical use of Kanglaite injection requires strict infusion speed and total volume, close monitoring of indicators such as blood lipids, blood routine, coagulation, and liver and kidney function. Early detection and timely treatment can reverse the patient's condition, and the overall prognosis is good.